Fluoroquinolones and anaerobes

Clinical Infectious Diseases

Volumn 42, Issue 11, 2006, Pages 1598-1607

  Stein, Gary E ^a   Goldstein, Ellie J C ^b,c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c R M ALDEN RESEARCH LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFOXITIN; CILASTATIN; CIPROFLOXACIN; CLINDAMYCIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TIMENTIN; TROVAFLOXACIN;

ABDOMINAL INFECTION; AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANAEROBIC INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTEREMIA; BACTEROIDES; BITE WOUND; CLOSTRIDIUM DIFFICILE; DIABETIC FOOT; DRUG POTENTIATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PERIODONTAL DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; FLUOROQUINOLONES; HUMANS;

EID: 33646736150     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/503907     Document Type: Review

References (106)

1. Fernandes PB, Shipkowitz N, Bower RR, Jarvis KP, Weisz J, Chu DTW. In-vitro and in-vivo potency of five new fluoroquinolones against anaerobic bacteria. J Antimicrob Chemother 1986; 18:693-701.
2. Goldstein EJC, Citron DM. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria. Antimicrob Agents Chemother 1992; 36: 1158-62.
3. Goldstein EJC. Possible role of the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety. Clin Infect Dis 1996; 23(Suppl 1): S25-30.
4. Finegold SM, Molitoris E, Reeves D, Wexler HM. In-vitro activity of temafloxacin against anaerobic bacteria: a comparative study. J Antimicrob Chemother 1991; 28(Suppl C):25-30.
5. Brook I. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities. Antimicrob Agents Chemother 1993; 37:997-1000.
6. Zabinsk RA, Vance-Bryan K, Krinke AJ, Walker KJ, Moody JA, Rotschafer JC. Evaluation of activity of temafloxacin against Bacteroides fragilis by an in-vitro pharmacodynamic system. Antimicrob Agents Chemother 1993; 37:2454-8.
7. Thadepalli H, Reddy U, Chuah SK, et al. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Antimicrob Agents Chemother 1997; 41:583-6.
8. Stearne LET, Gyssens IC, Goessens WHF, et al. In vivo efficacy of trovafloxacin against Bacteroides fragilis in a mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model. Antimicrob Agents Chemother 2001; 45:1394-401.
9. Hecht DW, Wexler HM. In vitro susceptibility of anaerobes to quinolones in the United States. Clin Infect Dis 1996; 23(Suppl 1):S2-8.
10. Wexler HM, Molitoris E, Molitoris D, Finegold SM. In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections. Antimicrob Agents Chemother 1998; 42:984-6.
11. Stein GE, Goldstein EJC. Review of the in vitro activity and potential clinical efficacy of levofloxacin in the treatment of anaerobic infections. Anaerobe 2003; 9:75-81.
12. MacGowan AP, Bowker KE, Holt M, Wooton M, Reeves DS. Bay12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria. J Antimicrob Chemother 1997; 40:503-9.
13. Shaumann R, Ackerman G, Pless B, Claros MC, Radloff AE. In vitro activities of gatifloxacin, two other quinolones, and five non-quinolone antimicrobials against obligately anaerobic bacteria. Antimicrob Agents Chemother 1999; 43:2783-6.
14. Stein GE, Schooley S, Tyrrell KL, Citron DM, Goldstein EJC. Bactericidal activities of methoxyfluoroquinolones gatifloxacin and maxifloxacin against aerobic and anaerobic respiratory pathogens in serum. Antimicrob Agents Chemother 2003; 47:1308-12.
15. Goldstein EJC, Citron DM, Warren Y, Tyrrell K, Merriam CV. In vitro activity of gemifloxacin (SB 265805) against anaerobes. Antimicrob Agents Chemother 1999; 43:2231-5.
16. Hecht DW, Osmolski JR. Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates. Antimicrob Agents Chemother 2003; 47:910-6.
17. Edminston CE, Krepel CJ, Kehl KS, et al. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients. J Antimicrob Chemother 2005; 56:872-8.
18. Goldstein EJC, Conrads G, Citron DM, Merriam CV, Warren Y, Tyrrell K. In vitro activity of gemifloxacin compared to seven other oral antimicrobial agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. Diagn Microbiol Infect Dis 2002; 42:113-8.
19. Snydman DR, Jacobus NV, McDermott LA, et al. In vitro activities of newer quinolones against Bacteroides group organisms. Antimicrob Agents Chemother 2002; 46:3276-9.
20. Goldstein EJC, Citron DM, Merriam CV, Tyrrell K, Warren Y. Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections. Antimicrob Agents Chemother 1999; 43:1475-9.
21. Milazzo IM, Blandino G, Mususmeci R, Nicoletti G, Lo Bue AM, Speciale A. Antibacterial activity of moxifloxacin against periodontal anaerobic pathogens involved in systemic infections. Int J Antimicrob Agents 2002; 20:451-6.
22. Sobottka I, Cachovan G, Sturenburg E, et al. In vitro activity of moxifloxacin against bacteria isolated from odontogenic abscesses. Antimicrob Agents Chemother 2002; 46:4019-21.
23. Goldstein EJC, Citron DM, Merriam CB, Warren YA, Tyrrell KL, Fernandez HT. In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. Antimicrob Agents Chemother 2003; 47:3008-11.
24. Citron DM, Appleman MD. Comparative in vitro activities of trovafloxacin (CP-99, 219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections. Antimicrob Agents Chemother 1997; 41:2312-6.
25. Credito KL, Jacobs MR, Appelbaum PC. Time-kill studies of the antianaerobic activity of garenoxacin compared with those of nine other agents. Antimicrob Agents Chemother 2003; 47:1399-402.
26. Hoellman DB, Kelly LM, Jacobs MR, Appelbaum PC. Comparative antianaerobic activity of BMS 284756. Antimicrob Agents Chemother 2001; 45:589-92.
27. Edminston CE, Krepel CJ, Seabrook GR, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004; 48:1012-6.
28. Goldstein EJC, Citron DM, Merriam CV, Tyrrell K, Warren Y. Activities of gemifloxacin (SB 265 805, LB 20304) compared to those of other oral antimicrobial agents against unusual anaerobes. Antimicrob Agents Chemother 1999; 43:2726-30.
29. Goldstein EJC, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez H. In vitro activities of the des-fluoro(6) quinolone BMS-284756 against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections. Antimicrob Agents Chemother 2002; 46:866-70.
30. Goldstein EJC, Citron DM, Nesbit C. Comparative activity of sparfloxacin, levofloxacin, and eight other oral agents against bacteria isolated from consecutive cases of diabetic foot infection. Diabetes Care 1996; 19:638-41.
31. Aldridge KE, Ashcraft DS. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother 1997; 41: 709-11.
32. Horn R, Robson HG. Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents. J Antimicrob Chemother 2001; 48:127-30.
33. Goldstein EJC, Citron DM, Warren YA, Merriam CV, Fernandez H. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2006; 50:148-55.
34. Goldstein EJC, Citron DM, Vaidya SA, et al. In vitro activity of 11 antibiotics against 74 anaerobes isolated from pediatric intra-abdominal infections. Anaerobe 2006; 12:63-6.
35. Ednie LM, Jacobs MR, Appelbaum PC. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob Agents Chemother 1998; 42:2459-62.
36. Kleinkauf N, Ackerman G, Schaumann R, Rodloff AC. Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria. Antimicrob Agents Chemother 2001; 45:1896-9.
37. Aldridge KE, Ashcraft D, O'Brien M, Sanders CV. Bacteremia due to Bacteroides fragilis group: distribution of species, β-lactamase production, and antimicrobial susceptibility patterns. Antimicrob Agents Chemother 2003; 47:148-53.
38. Zabinski RA, Walker KJ, Larsson AJ, Moody JA, Kaatz GW, Rotschafer JC. Effect of aerobic and anaerobic environment on anti-staphylococcal activities of five fluoroquinolones. Antimicrob Agents Chemother 1995; 39:507-12.
39. Boswell FJ, Andrews JM, Wise R. Bactericidal activity of trovafloxacin under anaerobic and aerobic conditions. Infect Dis Clin Pract 1996; 5(Suppl 3):113-6.
40. Pendland SL, Diaz-Linares M, Garey KW, Woodland JG, Ryu S, Danziger LH. Bactericidal activity and post-antibiotic effect of levofloxacin against anaerobes. Antimicrob Agents Chemother 1999; 43:2547-9.
41. Spangler SK, Jacobs MR, Appelbaum PC. Bacterial activity of DU-6859a compared to activities of three quinolones, three β-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology. Antimicrob Agents Chemother 1997; 41:847-9.
42. Stearne LET, KooiC, Goessens WHF, Bakker-Woudenberg IAJM, Gyssens IC. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique. Antimicrob Agents Chemother 2001; 45:243-51.
43. Schaumann R, Goldstein EJC, Forberg J, Rodloff AC. Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures. J Med Microbiol 2005; 54:749-53.
44. Boeckh M, Lode H, Deppermann KM, et al. Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. Antimicrob Agents Chemother 1990; 34:2407-14.
45. Goldstein EJC, Citron DM. Susceptibility of anaerobic bacterium isolated from intra-abdominal infections to ofloxacin and interaction of ofloxacin with metronidazole. Antimicrob Agents Chemother 1991; 35:2447-9.
46. Credito KL, Jacobs MR, Appelbaum PC. Anti-anaerobic activity of levofloxacin alone and combined with clindamycin and metronidazole. Diagn Microbiol Infect Dis 2000; 38:181-3.
47. Barry AL, Brown SD. Anaerobic activity of levofloxacin and metronidazole separately and in combination. J Antimicrob Chemother 1996; 37:1178-9.
48. Ednie LM, Credito KL, Khantipong M, Jacobs MR, Appelbaum PC. Synergistic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods. J Antimicrob Chemother 2000; 45:633-8.
49. Oh H, El Amin N, Davies T, Appelbaum PC, Edlund C. gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains. Antimicrob Agents Chemother 2001; 45:1977-81.
50. Ricci V, Peterson ML, Rotschafer JC, Wexler H, Piddock LJV. Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants. Antimicrob Agents Chemother 2004; 48:1344-6.
51. Miyamae S, Ueda O, Yoshimura F, Hwang J, Tanaka Y, Nikaido H. A MATE family multidrug effux transporter pumps out fluoroquinolones in Bacteroides thetaiotaomicron. Antimicrob Agents Chemother 2001; 45:3341-6.
52. Peterson ML, Rotschafer JC, Piddock LJV. Plasmid-mediated complementation of gyrA and gyrB in fluoroquinolone-resistant Bacteroides fragilis. J Antimicrob Chemother 2003; 52:481-4.
53. Ricci V, Piddock L. Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones. J Antimicrob Chemother 2003; 52:605-9.
54. Dridi L, Tankovic J, Burghoffer B, Barbut F, Petit JC. gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother 2002; 46:3418-21.
55. Ackerman G, Tang YJ, Kueper R, et al. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutilations in gyrA. Antimicrob Agents Chemother 2001; 45:2348-53.
56. Rafi F, Park M, Novak JS. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Antimicrob Agents Chemother 2005; 49:488-92.
57. Kato N, Miyauchi M, Muto Y, Watanabe K, Ueno K. Emergence of fluoroquinolone resistance in Bacteroides fragilis accompanied by resistance to β-lactam antibiotics. Antimicrob Agents Chemother 1988; 32:1437-8.
58. Snydman DR, Jacobus NV, McDermott LA, et al. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995-1996, with comparison of resistance trends from 1990 to 1996. Antimicrob Agents Chemother 1999; 43:2417-22.
59. Golan Y, McDermott LA, Jacobus NV, et al. Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother 2003; 52:208-13.
60. Oteo-Iglesias J, Alos JI, Gomery-Garces JL. Increase in resistance to new fluoroquinolones from 1998 to 2001 in the Bacteroides fragilis group. J Antimicrob Chemother 2002; 50:1055-7.
61. Betriu C, Rodriguez-Avial I, Gomez M, Culebras E, Picazo JJ. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6 year period (1997-2002). Diagn Microbiol Infect Dis 2005; 53:221-3.
62. Edlund C, Nord CE. A review on the impact of 4-quinolones on the normal oropharyngeal and intestinal human microflora. Infection 1988; 16:8-12.
63. Spencer RC. The role of antimicrobial agents in the aetiololgy of Clostridium difficile disease. J Antimicrob Chemother 1998; 41(Suppl C):21-7.
64. Golledge CL, Carson CF, O'Neill GL, Bowman RA, Riley TV. Ciprofloxacin and Clostridium difficile-associated diarrhea. J Antimicrob Chemother 1992; 30:141-7.
65. Yip C, Loeb M, Salama S, Moss L, Olde J. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 2001; 22:572-5.
66. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26:273-80.
67. McCusker ME, Harris AD, Perencevich E, Rughmann MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003; 9:730-3.
68. Rao GG, Mahankali Rao CS, Starke I. Clostridium difficile-associated diarrhea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with β-lactam-based therapy. J Antimicrob Chemother 2003; 51:697-701.
69. Khan R, Cheesbrough J. Impact of change in antibiotic policy on Clostridium difficile-associated diarrhea (CDAD) over a five-year period in a district general hospital. J Hosp Infect 2003; 54:104-8.
70. Mendez MN, Gibbs L, Jacobs RA, McCulloch CE, Winston L, Gugleilmo BJ. Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and rate of vancomycin-resistant enterococci and Clostridium difficile infections. Pharmacotherapy 2006; 26:61-7.
71. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004; 38:640-5.
72. Khurana A, Vinayek N, Recco RA, Go ES, Zaman MM. The incidence of Clostridium difficile-associated and non C. difficile-associated diarrhea after use of gatifloxacin and levofloxacin in an acute care facility. Clin Infect Dis 2004; 39:602-3.
73. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254-60.
74. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9.
75. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433-41.
76. Donskey CJ, Helfand MS, Pultz NJ, Rice LB. Effect of parenteral fluoroquinolone administration and persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. Antimicrob Agents Chemother 2004; 48:326-8.
77. Donskey CJ, Chowdhry TK, Hecken MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000; 343:1925-32.
78. Manzella J, Benenson R, Pellerin G, et al. Choice of antibiotic and risk of colonization with vancomycin-resistant Enterococcus among patients admitted for treatment of community-acquired pneumonia. Infect Control Hosp Epidemiol 2000; 21:789-91.
79. Ambrose PG, Bhavnani SM, Owens RC. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 2003; 17:529-43.
80. Ross GH, Wright DH, Hovde LB, Peterson ML, Rotschafer JC. Fluoroquinolone resistance in anaerobic bacteria following exposure to levofloxacin, trovafloxacin, and sparfloxacin in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2001; 45:2136-40.
81. Peterson ML, Hovde LB, Wright DH, Brown GH, Hoang AD, Rotschafer JC. Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2002; 46:203-10.
82. Noel AR, Bowker KE, MacGowan AP. Pharmacodynamics of moxifloxacin against anaerobes studied in an In vitro pharmacokinetic model. Antimicrob Agents Chemother 2005; 49:4234-9.
83. Sprandel KA, Schriever CA, Pendland SL, et al. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. Antimicrob Agents Chemother 2004; 48:4597-605.
84. Hermsen ED, Hovde LB, Sprandel KA, Rodvold KA, Rotschafer JC. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2005; 49:685-9.
85. Stein GE, Citron DM, Tyrrell K, Goldstein EJC. Serum bactericidal activity of trovafloxacin against selected anaerobic pathogens. Anaerobe 2001; 7:237-40.
86. Girard AE, Girard D, Gootz TD, Faiella JA, Cimochowski CR. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob Agents Chemother 1995; 39:2210-6.
87. Onderdonk AB. Efficacy of trovafloxacin (CP-99,219), a new fluoroquinolone, in an animal model of intra-abdominal sepsis. Infect Dis Clin Pract 1996; 5(Suppl 3):117-9.
88. Schaumann R, Blatz R, Beer J, Ackerman G, Rodloff AC. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli. J Antimicrob Chemother 2004; 53:318-24.
89. Madan AK. Use of ciprofloxacin in the treatment of hospitalized patients with intra-abdominal infections. Clin Ther 2004; 26:1564-77.
90. Fass RJ. Treatment of skin and soft tissue infections with oral ciprofloxacin. J Antimicrob Chemother 1986; 18(Suppl D):153-7.
91. Wood MJ, Logan MN. Ciprofloxacin for soft tissue infections. J Antimicrob Chemother 1986; 18(Suppl D):159-64.
92. Crombleholme WR, Schachter J, Ohm-Smith M, Luft J, Whidden R, Sweet RL. Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin. Am J Med 1989; 87(Suppl 5A):142S-7S.
93. Thadepalli H, Mathai D, Scotti R, Bansal MB, Savage E. Ciprofloxacin monotherapy for acute pelvic infections: a comparison with clindamycin plus gentamicin. Obstet Gynecol 1991; 78:696-701.
94. Starakis I, Karravias D, Asimakopoulos C, et al. Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral) + metronidazole (intravenous/oral) with ceftriaxone (intravenous) + metronidazole (intravenous/oral) for the treatment of intra-abdominal infections. Int J Antimicrob Agents 2003; 21:49-57.
95. Solomkin JS, Reinhart HH, Patchen Dellinger E, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. Ann Surg 1996; 223:303-15.
96. Cohn SM, Lipsett PA, Buchman TH, et al. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intra-abdominal infections. Ann Surg 2000; 232:254-62.
97. Donahue PE, Smith DL, Yellin AE, Mintz SJ, Bur F, Luke DR. Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Am J Surg 1998; 176(Suppl 6A):53-61.
98. Roy S, Koltun W, Chatwani A, Martins MG, Dittrich R, Luke DR. Treatment of acute gynecologic infections with trovafloxacin. Am J Surg 1998; 176(Suppl 6A):67-73.
99. Yamada Y, Mikamo H, Izumi K, Ito K, Tamaya T. Basic and clinical studies of levofloxacin in obstetrics and gynecology. Drugs 1993; 45(Suppl 3):385.
100. Nicrodemo AC, Robledo JA, Jasvovich A, Neto W. A multicentre, double-blind, randomized study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections. Int J Clin Pract 1998; 52: 69-74.
101. Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate for complicated skin and skin-structure infections: a randomized open-label trial. Clin Infect Dis 2002; 35:381-9.
102. Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents 2005; 26:357-65.
103. Malangoni M, Song J, Choudhri S, Potgieter P, Cyrus P. Sequential IV/PO moxifloxacin vs IV piperacillin-tazobactam +/- PO amoxicillin-clavulanate for treatment of complicated intra-abdominal infections. Ann Surg (in press).
104. Goldstein EJC. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents. Clin Infect Dis 2002; 35(Suppl 1):S106-11.
105. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38(Suppl 4):S341-5.
106. Hecht DW. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin Infect Dis 2004; 39:92-7.